Moderna cancer drug faces high investor bar; small setbacks loom

Investor expectations for Moderna's cancer vaccine are elevated, making the stock sensitive to minor clinical or regulatory setbacks. The article discusses the risk of disappointment despite promising data, highlighting the gap between market pricing and trial realities. This matters because any negative readout could trigger sharp sell-offs in a high-multiple biotech name.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works